homepage-top-section

The regulator has approved the therapy as a potential new standard of care to treat Pompe disease, a rare, progressive and severe muscle disorder. Individuals with this disease

A fully human biologic, Cosentyx has been developed to directly inhibit interleukin-17A (IL-17A), a cytokine. The regulatory approval is granted for the use of the therapy, either alone

The combination therapy is indicated to treat unresectable or metastatic solid tumours with the BRAF V600E mutation in adult and paediatric patients aged six years and above whose

Imcivree is a melanocortin-4 receptor (MC4R) agonist which is indicated for chronic weight management in adult and paediatric patients aged six years and above with monogenic or syndromic

Atogepant is an oral calcitonin gene-related peptide [CGRP] receptor antagonist (gepant) which has been specifically developed as the preventive migraine treatment. In September last year, the drug received

The funding round was co-led by an industrial investment firm and MSA Capital. Sherpa Healthcare Partners, 3H Health Investment, and the company’s existing investors Quan Capital and Cenova

With this FDA approval, IMCIVREE is indicated for chronic weight management in adult and pediatric patients aged six years and older with monogenic or syndromic obesity due to

This agreement will allow Quoin to offer healthcare professionals and patients in greater China, including Hong Kong, Macau and Taiwan, with access to its products following receipt regulatory

A pre-clinical stage biotech company, Trutino Biosciences is engaged in discovering and developing next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim has a two-pronged research